Physician profile
Edwin C Chan
NPI 1124142054
$2,542.77
in general payments reported to CMS, 2019-2025
23 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $76.89 · 2021: $230 · 2022: $521 · 2023: $442 · 2024: $239 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $511.75 | 2021-2023 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $442.46 | 2019-2022 | |
| Novo Nordisk INC | $439.68 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $254.31 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $188.57 | 2019-2024 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $178.35 | 2025 | Voquezna |
| Exact Sciences Corporation | $103.72 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $95.95 | 2019-2025 | |
| Abbott Laboratories | $41.61 | 2019-2022 | |
| Shield Therapeutics INC | $40.62 | 2023-2024 | Accrufer |
| Boston Scientific Corporation | $33.78 | 2025 | Watchman Flx |
| Astellas Pharma US INC | $26.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.06 | 2019-2022 | |
| Daiichi Sankyo INC. | $21.56 | 2022 | |
| Nevro Corp. | $20.66 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $19.44 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.36 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $17.22 | 2025 | Farxiga |
| Medtronic, INC. | $13.70 | 2022 | |
| Antares Pharma, INC. | $13.65 | 2020 | |
| Eisai INC. | $12.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.10 | 2022 | |
| Merck Sharp & Dohme LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.